📖 Complete Guide✅ Updated 2026🔬 Evidence-Based

Egrifta (Tesamorelin) Guide

Dosing & Fat Loss 2026

Complete guide to Egrifta (Tesamorelin). Understand how this FDA-approved GHRH peptide targets visceral fat, proper dosing protocols, and side effects.

Last reviewed: March 2026

Download on theApp Store

Get it onGoogle Play

FDA-Approved Visceral Fat Reduction

Egrifta (generic name Tesamorelin) is an FDA-approved growth hormone-releasing hormone (GHRH) analogue. Originally approved specifically to reduce excess abdominal fat (lipodystrophy) in HIV patients, it is now widely utilized off-label for aggressive visceral fat reduction and body recomposition.

What Is Egrifta (Tesamorelin) Guide?

Unlike synthetic human growth hormone (hGH), Egrifta stimulates your own pituitary gland to pulse natural growth hormone into the bloodstream, preserving the delicate feedback loop and minimizing tachyphylaxis (receptor burnout).

Key Biohacking Mechanics

Selectively targets visceral adipose tissue surrounding internal organs

Stimulates lipolysis directly at the adipocyte via GH-receptor binding

Clinical trials: average 18% reduction in visceral fat within 26 weeks

Binds to GHRH receptors in the anterior pituitary

Causes pulsatile (natural) GH surges, unlike continuous exogenous GH

Increases serum IGF-1 levels for anabolism and recovery

Dosing Protocol

Injected daily (subcutaneous) for HIV lipodystrophy.

Often used in anti-aging or fitness for body recomp.

Bedtime or morning on empty stomach to maximize GH pulse.

Note: Carbohydrates and insulin flatline GH release. Injecting Egrifta after an insulin-spiking meal renders it virtually useless.

Side Effects & Safety

🔬

Common Effects

Injection site reactions (redness, swelling). Joint pain and muscle aches. Peripheral edema (mild water retention). Paresthesia (tingling in extremities)

📱

Monitoring Required

May worsen glucose tolerance — monitor fasting glucose. IGF-1 levels should be checked periodically. Discontinue if active malignancy suspected. Not recommended during pregnancy

Vital Protocol FAQs

🔬

What is the difference between Egrifta and Egrifta SV?

Egrifta SV (Single Vial) is the newer formulation that achieves the standard 2mg dose using a much smaller volume of sterile water, making the injection faster and less visibly irritating.

⚖️

Does it work for subcutaneous fat?

While it primarily excels at shrinking visceral (organ) fat, the systemic increase in GH/IGF-1 will eventually promote the breakdown of standard subcutaneous fat over a 3 to 6-month cycle.

🔬

Do you have to cycle Egrifta?

Yes, most practitioners suggest a 5 days on, 2 days off protocol, or cycles lasting 12-16 weeks followed by a 4-week break. This prevents pituitary desensitization.

Guide FAQs